BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer

被引：0
作者：
Sampson, E. L.
Valero, V.
Roche, H.
Pienkowski, T.
Canon, J.
Zhao, Y.
Carney, W.
Mackey, J.
Taupin, H.
Lindsay, M.
Buyse, M.
Slamon, D.
机构：
[1] Siemens Med Solut Diagnost, Tarrytown, NY USA
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Inst Claudius Regaud, Toulouse, France
[4] MS Curie Mem Canc Ctr, Warsaw, Poland
[5] CH Notre Dame, Charleroi, Belgium
[6] Univ Calif Los Angeles, Los Angeles, CA USA
[7] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[8] CIRG, Paris, France
[9] CIRG, Edmonton, AB, Canada
[10] IDDI, Louvain, Belgium
来源：
CLINICAL CHEMISTRY | 2007年 / 53卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
A109
引用
收藏
页码：A34 / A34
页数：1
相关论文
共 50 条
[31]   Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells. [J].
Fehm, T. ;
Lane, N. ;
Solomayer, E. ;
Wallwiener, D. ;
Uhr, J. .
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 :S40-S40
[32]   The conditional requirement of HER3 in HER2-amplified breast cancers [J].
Ruiz-Saenz, Ana ;
Dreyer, Courtney ;
Steri, Veronica ;
Campbell, Marcia ;
Gulizia, Nathaniel ;
Moasser, Mark .
MOLECULAR CANCER RESEARCH, 2018, 16 (08) :94-95
[33]   Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer [J].
Singer, C. F. ;
Tan, Y. Y. ;
Fitzal, F. ;
Steger, G. G. ;
Egle, D. ;
Reiner, A. ;
Rudas, M. ;
Gruber, C. ;
Bartsch, R. ;
Fridrik, M. ;
Seifert, M. ;
Exner, R. ;
Balic, M. ;
Bago-Horvath, Z. ;
Filipits, M. ;
Gnant, M. .
CANCER RESEARCH, 2017, 77
[34]   Tumor infiltrating lymphocytes before and after dual HER2 blockade in HER2-amplified early breast cancer: A TRYPHAENA substudy. [J].
Ignatiadis, Michail ;
Van den Eynden, Gert G. ;
Salgado, Roberto ;
Fornili, Marco ;
Desmedt, Christine ;
Holgado, Esther ;
McNally, V. A. ;
Kiermaier, Astrid Christina ;
Cortes, Javier ;
Schneeweiss, Andreas ;
Willard-Gallo, Karen ;
Biganzoli, Elia ;
Sotiriou, Christos .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[35]   THE POTENTIAL IMPACT OF USING CHANGES IN SERUM HER2 LEVELS TO INITIATE THERAPY CHANGE IN HER2+METASTATIC BREAST CANCER [J].
Noy, K. ;
Dejori, M. ;
Ghosh, P. ;
Suhail, A. M. ;
Leitzel, K. ;
Lipton, A. ;
Carney, W. ;
Wittenberg, G. .
VALUE IN HEALTH, 2010, 13 (03) :A40-A40
[36]   Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer [J].
Singer, Christian F. ;
Tan, Yen Y. ;
Fitzal, Florian ;
Steger, Guenther G. ;
Egle, Daniel ;
Reiner, Angelika ;
Rudas, Margaretha ;
Moinfar, Farid ;
Gruber, Christine ;
Petru, Edgar ;
Bartsch, Rupert ;
Tendl, Kristina A. ;
Fuchs, David ;
Seifert, Michael ;
Exner, Ruth ;
Balic, Marija ;
Bago-Horvath, Zsuzsanna ;
Filipits, Martin ;
Gnant, Michael .
CLINICAL CANCER RESEARCH, 2017, 23 (14) :3676-3683
[37]   Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside [J].
Tsang, Roger Y. ;
Sadeghi, Saeed ;
Finn, Richard S. .
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2011, 3 :1-13
[38]   Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells [J].
Fehm, T. ;
Solomayer, E. ;
Uhr, J. ;
Wallwiener, D. .
ONKOLOGIE, 2008, 31 :51-51
[39]   Successful targeting HER2 in heavily pretreated HER2-negative metastatic breast cancer patients presenting with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells [J].
Kurbacher, C. M. ;
Quade, A. ;
Eichler, C. ;
Kunstmann, G. ;
Herz, S. ;
Kurbacher, J. A. ;
Warm, M. R. .
CANCER RESEARCH, 2016, 76
[40]   Regarding HER2-Amplified Biliary Tract Cancer [J].
Pant, Shubham .
ONCOLOGIST, 2021, 26 (09) :E1664-E1664
12345